Yoshioka H, Nishimura O, Nakagawa M, Ochi M, Takeuchi Y, Tominaga M, Hasegawa K, Osamura T, Goma H, Sawada T
Department of Pediatrics, Kyoto Prefectural University of Medicine, Japan.
Brain Dev. 1989;11(5):302-7. doi: 10.1016/s0387-7604(89)80057-9.
Between 1979 and 1982, fifteen patients with SSPE were treated with human leukocyte interferon (HuIFN-alpha). They were administered interferon (IFN) in doses ranging from 25 x 10(6) IU to 126 x 10(6) IU by various routes in regimens that ranged for 20 days to 14 months. In 3 of the 5 cases with rapid deterioration, HuIFN-alpha did not alter the course of the disease; however, 6 cases with mild progression showed various degrees of clinical improvement during the IFN therapy. In 3 of the 4 cases in remission, HuIFN-alpha caused no significant changes in clinical courses. No severe adverse reactions were seen during IFN administration. These results suggest that HuIFN-alpha has a potentially beneficial effect on the course of SSPE.
1979年至1982年间，15例亚急性硬化性全脑炎（SSPE）患者接受了人白细胞干扰素（HuIFN-α）治疗。他们通过不同途径接受干扰素（IFN）治疗，剂量范围为25×10⁶国际单位至126×10⁶国际单位，疗程从20天至14个月不等。在5例病情迅速恶化的患者中，有3例HuIFN-α并未改变疾病进程；然而，6例病情轻度进展的患者在干扰素治疗期间显示出不同程度的临床改善。在4例缓解期患者中，有3例HuIFN-α未引起临床病程的显著变化。在干扰素给药期间未观察到严重不良反应。这些结果表明，HuIFN-α对SSPE的病程可能具有有益作用。
